BEIGF 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• On July 23, 2026, we announced a $300 million expansion of our flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, to add small molecule manufacturing capabilities.

• On June 30, 2026, we announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306) evaluating foundational Bruton’s tyrosine kinase (“BTK”) inhibitor BRUKINSA® plus rituximab versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma (“MCL…

• On May 13, 2026, we announced that the U.S. Food and Drug Administration (“FDA”) granted accelerated approval to BEQALZI™ (sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) MCL, after at least two lines of systemic the…

• The following table summarizes our results of operations for the three and six months ended June 30, 2026 and 2025:

• Total revenue increased to $1,705.1 million for the three months ended June 30, 2026, from $1,315.3 million for the three months ended June 30, 2025, due to increased sales of BRUKINSA, TEVIMBRA, as well as increased sales of in-licensed products from Amgen.

相对上期删除的文字 · 来源:10-Q · 2026-05-06

• •Received Orphan Drug Designation in Japan for the treatment of adult patients with relapsed or refractory (“R/R”) marginal zone lymphoma (“MZL”).

• •Submitted New Drug Application in Japan for R/R MZL and tablet formulation.

• •Launched and commercially available in China for the treatment of adult patients with R/R mantle cell lymphoma (“MCL”) and R/R chronic lymphocytic leukemia (“CLL”)/small lymphocytic lymphoma (“SLL”).

• •Included in the European Society of Medical Oncology (“ESMO”) guidelines as a recommended third-line treatment for R/R MCL patients.

• •Received acceptance of a Supplemental Biologics License Application (“sBLA”) by the U.S. Food and Drug Administration (“FDA”) with Priority Review for the treatment of adult patients with first-line HER2-positive gastroesophageal adenocarcinoma (“GEA”) in combination with ZIIHERA (zanidatamab) and …

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• We are regularly under examination by tax authorities, including U.S. and non-U.S. tax authorities. The final resolution of any tax examinations could result in unanticipated increases in our tax expense and changes to the timing of required tax payments, which could affect our cash flows for any pa…

相对上期删除的文字 · 来源:10-Q · 2026-05-06

• We are regularly under examination by tax authorities, including U.S. and non-U.S. tax authorities (PRC, Switzerland and other countries). The final resolution of any related administrative reviews or litigation could result in unanticipated increases in our tax expense and changes to the timing of …

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• Effective as of August 3, 2026, the Swiss Articles were amended to reflect changes in the Company’s total issued share capital resulting from the issuance to one of the Company’s wholly-owned subsidiaries of 866,073 of the Company’s fully paid-up registered shares with a nominal value of $0.0001 eac…

• A copy of the Company’s amended Swiss Articles is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

• Up to 9,353 ADSs plus up to such additional number of ADSs subject to restricted share units (“RSUs”) equal to the net number of ADSs resulting from applicable RSU vestings after sell-to-cover for withholding tax.

相对上期删除的文字 · 来源:10-Q · 2026-05-06

• (Co-Founder, Chief Executive Officer, and Chairman of the Board of Directors)

• (ii)up to such net number of ADSs to be received upon vesting of unvested RSUs in 2026 after sell-to-cover for withholding tax, to be sold by Mr. Oyler; and

• (iii)up to 60,010 ADSs to be sold by the Pan-Oyler Foundation.